ArticleMediators of inflammation2026
Moxibustion Modulates ALOX15-Mediated Lipid Peroxidation to Inhibit Ferroptosis in Synovial Inflammatory Injury of Rheumatoid Arthritis.
Article in Mediators of inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Moxibustion Modulates ALOX15-Mediated Lipid Peroxidation to Inhibit Ferroptosis in Synovial Inflammatory Injury of Rheumatoid Arthritis.Mediators of inflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease characterized by synovial, cartilage, and bone damage. Emerging research evidence has linked its pathogenesis to ferroptosis, arachidonic acid (ARA) metabolism, and lipid peroxidation. Lipid peroxidation serves as the final executor of ferroptosis, and arachidonate lipoxygenase (ALOX)-mediated oxidative reactions enzymatically promote lipid peroxidation. Moxibustion (MOX), a traditional therapeutic modality in Chinese medicine, has demonstrated significant efficacy in our study. Specifically, MOX applied at the Zusanli (ST36) and Shenshu (BL23) acupoints effectively ameliorated paw swelling in Freund's complete adjuvant (FCA)-induced RA model rats, significantly reduced arthritis scores, and corrected ARA metabolic dysregulation. Furthermore, MOX treatment markedly decreased the expression levels of arachidonate 15-lipoxygenase (ALOX15), acyl-CoA synthetase long-chain family member 4 (ACSL4), lysophosphatidylcholine acyltransferase 3 (LPCAT3), and reactive oxygen species (ROS) in the synovial tissues of RA model rats while increasing the expression of ferritin heavy chain 1 (FTH1) and glutathione peroxidase 4 (GPX4). Serum analyses revealed significant reductions in malondialdehyde (MDA), lipid peroxide (LPO), interleukin-12 (IL-12), and tumor necrosis factor-alpha (TNF-α) levels, alongside elevated glutathione (GSH) and superoxide dismutase (SOD) levels. The underlying mechanism involves the modulation of ALOX15-mediated lipid peroxidation to inhibit ferroptosis, thereby alleviating RA-associated inflammatory damage. These findings highlight the substantial therapeutic potential of MOX in mitigating RA-related inflammation and provide a novel theoretical basis for its clinical application in RA management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.